Skip to main content
Ascendis Pharma A/S logo

Ascendis Pharma A/S — Investor Relations & Filings

Ticker · ASND ISIN · US04351P1012 LEI · 549300B66JN3W3J8GH73 US Manufacturing
Open in API
Filings indexed 715 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country DK Denmark
Listing US ASND

About Ascendis Pharma A/S

https://ascendispharma.dk/

Ascendis Pharma is a biopharmaceutical company that applies its proprietary TransCon (Transient Conjugation) technology platform to develop new therapies. The company's focus is on addressing unmet medical needs in rare diseases, with primary therapeutic areas in endocrinology and oncology. The TransCon technology is designed to create prodrugs that provide a predictable and sustained release of an unmodified parent drug, aiming to improve treatment outcomes for patients. Through this platform, Ascendis Pharma is advancing a pipeline of product candidates and is building a fully integrated biopharmaceutical organization.

Recent filings

Filing Released Lang Actions
SD
Regulatory Filings Classification · 85% confidence The document is an SEC Form SD (“Specialized Disclosure Report”) filed under Rule 13p-1, containing conflict minerals disclosure and reference to an exhibit. It is a compliance/regulatory filing rather than a full financial report, management/strategy presentation, or transaction notice. It falls into the general “Regulatory Filings” (RNS) category as a specialized SEC compliance document.
2026-05-22 English
6-K - Ascendis Pharma A/S (0001612042) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer with the U.S. SEC, furnishing a press release as an exhibit. It does not itself contain substantive financial statements or detailed report content; rather, it serves as a regulatory submission under the Exchange Act. This fits the “Regulatory Filings” category.
2026-05-07 English
6-K - Ascendis Pharma A/S (0001612042) (Filer)
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K submitted by a foreign private issuer that contains the company’s unaudited condensed consolidated interim financial statements and Management’s Discussion and Analysis for the quarter ended March 31, 2026. It includes full financial statements for the three-month period and related notes, satisfying the definition of a comprehensive interim/quarterly report rather than merely announcing or referencing a report. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-07 English
6-K - Ascendis Pharma A/S (0001612042) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes administrative information such as ISIN updates and incorporation by reference statements but does not contain financial statements or detailed financial analysis. The document length is short (2214 characters) and primarily serves as a regulatory update rather than a full report. According to the rules, such filings that do not fit other categories and are regulatory announcements fall under Regulatory Filings (RNS).
2026-04-21 English
6-K - Ascendis Pharma A/S (0001612042) (Filer)
Regulatory Filings
2026-04-20 English
6-K - Ascendis Pharma A/S (0001612042) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Ascendis Pharma A/S, with the SEC. It announces the company's plan to directly list its ordinary shares on Nasdaq, replacing its American Depositary Shares (ADSs) with ordinary shares. The document details the mechanics and timing of the exchange and listing but does not contain financial statements or detailed financial analysis. It is an announcement of a corporate action related to capital structure and listing status, specifically about the direct listing and mandatory exchange of ADSs for ordinary shares. This fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital structure and listing status. The document is about a significant financing/capital event but is not a full financial report or earnings release.
2026-04-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.